Will PBMs' TrumpRx Price Pledge Reach Prescribers?

Citing increased transparency, affordability and consumer choice, 10 pharmacy benefit managers (PBMs) committed to displaying TrumpRx cash prices alongside benefit pricing within Real Time Benefit Tools (RTBTs), the point-of-prescribing systems doctors use to check patient costs, in coordination with the Centers for Medicare and Medicaid Services (CMS). Their trade group, the Pharmaceutical Care Management Association (PCMA), announced the commitment.^1,2

The participating PBMs pledged to present the cash prices listed on TrumpRx for comparison against a patient's benefit-based price, delivered through existing RTBTs, when consistent with plan coverage and allowed by law. CMS Administrator Dr. Mehmet Oz said the change would let patients see cost differences directly and choose accordingly, calling it the kind of transparency needed to spur competition and lower costs.¹

“Consumers and patients are better off when they have more options and a clear view of their costs. If there are times when a product is cheapest on TrumpRx, patients should know that,” said David Marin, president and CEO of PCMA, in a press release.²

The commitment builds on PCMA's characterization of the PBM industry's longstanding investment in real-time cost tools delivered through portals and apps, and follows continued scrutiny of whether TrumpRx, the Trump administration's most-favored-nation pricing platform launched in February, actually beats what patients already pay through insurance. A recent member survey by the Academy of Managed Care Pharmacy (AMCP) reported widespread skepticism among managed care professionals on that question, as Pharmaceutical Commerce previously reported.³

How Would the Price Comparison Feature Work?

Under the commitment, RTBTs used by prescribers will display the TrumpRx cash price for a drug next to the cost associated with filling the prescription under the patient's plan benefit at a pharmacy.¹ PBMs already use RTBTs to show doctors a range of treatment costs. The new element folds TrumpRx's cash-pay pricing into that same comparison.

In a statement to Pharmaceutical Commerce, Adam Colborn, vice president of government affairs at the AMCP, said the move addresses a real information gap, but noted it leans on a system with a documented adoption problem.

“This is a helpful move by managed care to facilitate patients’ ability to shop for the best price, but it’s dependent on patients’ access to real-time benefit tools,” Colborn said.⁴

How Often Do Physicians Actually Use RTBTs?

According to Colborn, RTBTs are effective at reducing patient costs when used, “but doctors rarely use them.” Physicians report opening the RTBT in only 1.3% to 13.5% of encounters.⁵ When the RTBT suggests a change, doctors accept it in only 11% of cases.⁶ All major PBMs offer RTBTs, and are mandated to do so in Part D, but only 55% of hospitals report using it for all or nearly all plans as of 2025.⁷ Further, employers sometimes do not opt in to the technology, Colborn noted.

“When enabled, price comparison tools are typically available to patients through their insurance portals. Because prescriptions are usually sent to pharmacies while the patient is still in their doctor’s office, they may not use the tool in their patient portal,” he added.

“Ultimately, this is an improvement to RTBTs, but doctors’ infrequent use of the tool will limit its impact,” Colborn said.

What Does AMCP's Survey Show About Real-World Confidence?

AMCP's June 2026 member survey, which drew 59 anonymous responses from health plans, PBMs, integrated delivery networks and consulting firms, surfaced doubt about whether TrumpRx beats insurance-based pricing.³

When asked how likely an insured patient is to find medication on TrumpRx at a lower cost than through insurance, given that across the board, TrumpRx purchases do not count toward a deductible, 21 respondents said unlikely, compared with 11 who said likely or very likely and 17 who were neutral.³ When asked more broadly how likely the TrumpRx platform is to lower US prescription drug costs overall, 26 respondents said unlikely and 18 said very unlikely, versus 11 who said likely or very likely.

What Does This Mean for Manufacturers' Channel Strategy?

For manufacturers with TrumpRx pricing agreements, the RTBT change puts a cash-pay price in direct, side-by-side view against the same product's negotiated formulary price at the moment a prescriber is deciding what to write. That visibility cuts both ways. A manufacturer whose TrumpRx cash price undercuts a payer's benefit-based cost could see prescribers and patients steered toward the cash channel, a dynamic that sits outside the rebate and formulary structure manufacturers negotiate with PBMs. Manufacturers without a TrumpRx deal get no comparable exposure in the tool.

The physician-adoption data Colborn cited suggests that exposure will be limited in the near term, and the practical effect of the commitment on any single manufacturer's channel mix will depend heavily on which prescribers' systems have adopted the tool and how it's configured there.

Whether the new price display changes prescribing behavior at scale depends on the same physician workflow constraints Colborn and the RTBT literature describe: display rates in the single digits to low teens, acceptance rates near 11% when a suggestion does appear and inconsistent employer opt-in even where the technology exists.

References

1. Pharmaceutical Care Management Association. What you need to know about the PBM industry's new TrumpRx commitment on transparency, affordability, and consumer choice. PCMA. August 20, 2026. Accessed August 20, 2026. https://www.pcmanet.org/pcma-blog/what-you-need-to-know-about-the-pbm-industrys-new-trumprx-commitment/
2. Pharmaceutical Care Management Association. In support of affordability, transparency and consumer choice, PBMs commit to presenting patients TrumpRx prices for their prescription drugs. Press release. August 2026. Accessed August 20, 2026. https://www.pcmanet.org/press-releases/in-support-of-affordability-transparency-and-consumer-choice-pbms-commit-to-presenting-patients-trumprx-prices-for-their-prescription-drugs/
3. Academy of Managed Care Pharmacy. TrumpRx Member Survey. June 2026.
4. Colborn A. Email statement to Pharmaceutical Commerce. August 20, 2026.
5. Kane RM, Morton-Oswald S, Lokhnygina Y, Maciejewski ML, Sloan CE. User-directed vs interruptive real-time benefit tools for medication changes in primary care. JAMA Netw Open. 2026;9(6):e2615767. Accessed August 20, 2026. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2849736
6. Klebanoff MJ, Li P, Chatterjee P, Doshi JA. Prescription real-time benefit tools: clinicians receive frequent alerts yet rarely accept the suggested changes. Health Aff (Millwood). Accessed August 20, 2026. https://www.healthaffairs.org/doi/10.1377/hlthaff.2025.00783
7. Office of the National Coordinator for Health Information Technology. Hospital adoption of real-time benefit tools. Health IT Quick Stat #67. Accessed August 20, 2026. https://healthit.gov/data/quickstats/hospital-adoption-real-time-benefit-tools/